Marion Wobser

Josef Schneider Str. 2
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: May 22, 2026

Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network.

Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network.

Journal: Cancers

Published: November 27, 2025

Haematopoietic stem cell transplantation for cutaneous T-cell lymphomas: Decision-guiding prognostic determinants yet to be clarified.

Haematopoietic stem cell transplantation for cutaneous T-cell lymphomas: Decision-guiding prognostic determinants yet to be clarified.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 23, 2025

DNA methylation-based classification of hematolymphoid neoplasms.

DNA methylation-based classification of hematolymphoid neoplasms.

Journal: Blood advances

Published: October 20, 2025

Mogamulizumab-associated rash and lymphocytopenia coinciding with treatment response of Sézary syndrome.

Mogamulizumab-associated rash and lymphocytopenia coinciding with treatment response of Sézary syndrome.

Journal: European journal of dermatology : EJD

Published: September 18, 2025

Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series.

Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series.

Journal: Case reports in dermatological medicine

Published: July 24, 2025

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.

Journal: Blood

Published: April 16, 2025

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: February 28, 2025

Topical ruxolitinib for treatment of mycosis fungoides and lymphomatoid papulosis.

Topical ruxolitinib for treatment of mycosis fungoides and lymphomatoid papulosis.

Journal: The British journal of dermatology

Published: February 19, 2025

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study.

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: February 10, 2025

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

Journal: The British journal of dermatology

Published: January 25, 2025

Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer.

Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer.

Journal: Cancer discovery

Published: December 19, 2024

Showing 1-12 of 113

Last Updated: 09/26/2026